Tags

Type your tag names separated by a space and hit enter

In vitro activity against anaerobes of retapamulin, a new topical antibiotic for treatment of skin infections.
J Antimicrob Chemother. 2007 Apr; 59(4):646-51.JA

Abstract

OBJECTIVES

Retapamulin is the first agent of the pleuromutilin class formulated as a topical antibacterial for treating skin infections. The aim of this study was to determine the antimicrobial activity of retapamulin by determining the minimal inhibitory concentration (MIC) values of this new drug and comparators against a wide range of anaerobic bacteria of human origin.

METHODS

The in vitro activity of retapamulin and six comparators (amoxicillin, amoxicillin/clavulanic acid, ceftriaxone, imipenem, clindamycin and metronidazole) was evaluated against 232 anaerobic clinical isolates. MICs were determined by the CLSI reference agar dilution method (M11-A6).

RESULTS

Ceftriaxone, clindamycin and amoxicillin/clavulanic acid resistance rates were 54%, 42% and 9.6%, respectively, within the Bacteroides fragilis group. Despite high resistance rates to various antibiotics, retapamulin inhibited 37/52 (71%) strains of the B. fragilis group and 85/87 (98%) of the other Gram-negative bacilli at a concentration of 2 mg/L or less. All the investigated strains of Clostridium perfringens were inhibited by 1 mg/L retapamulin. Three strains of C. difficile and one strain of C. clostridioforme demonstrated decreased susceptibility to retapamulin. Based on inhibitory concentrations, retapamulin was more active than clindamycin, metronidazole and ceftriaxone against Propionibacterium acnes and anaerobic Gram-positive cocci, as all isolates were inhibited by <or=2 mg/L.

CONCLUSIONS

At <or=2 mg/L, retapamulin inhibited 90% of all 232 anaerobes tested, whereas overall resistance rates for the comparators were as follows: co-amoxiclav, 2%; metronidazole, 12%; clindamycin, 15% and ceftriaxone, 20%. The broad anaerobic spectrum demonstrated by retapamulin in vitro is attractive. Pending further clinical investigation, retapamulin may offer an alternative treatment for anaerobic skin infections in this era of increasing resistance.

Authors+Show Affiliations

Faculty of Pharmacy, 3 rue du Professeur Laguesse, BP83, 59006 Lille Cedex, France. marie-francoise.odou@univ-lille2.frNo affiliation info availableNo affiliation info availableNo affiliation info available

Pub Type(s)

Journal Article
Research Support, Non-U.S. Gov't

Language

eng

PubMed ID

17350985

Citation

Odou, M-F, et al. "In Vitro Activity Against Anaerobes of Retapamulin, a New Topical Antibiotic for Treatment of Skin Infections." The Journal of Antimicrobial Chemotherapy, vol. 59, no. 4, 2007, pp. 646-51.
Odou MF, Muller C, Calvet L, et al. In vitro activity against anaerobes of retapamulin, a new topical antibiotic for treatment of skin infections. J Antimicrob Chemother. 2007;59(4):646-51.
Odou, M. F., Muller, C., Calvet, L., & Dubreuil, L. (2007). In vitro activity against anaerobes of retapamulin, a new topical antibiotic for treatment of skin infections. The Journal of Antimicrobial Chemotherapy, 59(4), 646-51.
Odou MF, et al. In Vitro Activity Against Anaerobes of Retapamulin, a New Topical Antibiotic for Treatment of Skin Infections. J Antimicrob Chemother. 2007;59(4):646-51. PubMed PMID: 17350985.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - In vitro activity against anaerobes of retapamulin, a new topical antibiotic for treatment of skin infections. AU - Odou,M-F, AU - Muller,C, AU - Calvet,L, AU - Dubreuil,L, Y1 - 2007/03/09/ PY - 2007/3/14/pubmed PY - 2007/6/15/medline PY - 2007/3/14/entrez SP - 646 EP - 51 JF - The Journal of antimicrobial chemotherapy JO - J Antimicrob Chemother VL - 59 IS - 4 N2 - OBJECTIVES: Retapamulin is the first agent of the pleuromutilin class formulated as a topical antibacterial for treating skin infections. The aim of this study was to determine the antimicrobial activity of retapamulin by determining the minimal inhibitory concentration (MIC) values of this new drug and comparators against a wide range of anaerobic bacteria of human origin. METHODS: The in vitro activity of retapamulin and six comparators (amoxicillin, amoxicillin/clavulanic acid, ceftriaxone, imipenem, clindamycin and metronidazole) was evaluated against 232 anaerobic clinical isolates. MICs were determined by the CLSI reference agar dilution method (M11-A6). RESULTS: Ceftriaxone, clindamycin and amoxicillin/clavulanic acid resistance rates were 54%, 42% and 9.6%, respectively, within the Bacteroides fragilis group. Despite high resistance rates to various antibiotics, retapamulin inhibited 37/52 (71%) strains of the B. fragilis group and 85/87 (98%) of the other Gram-negative bacilli at a concentration of 2 mg/L or less. All the investigated strains of Clostridium perfringens were inhibited by 1 mg/L retapamulin. Three strains of C. difficile and one strain of C. clostridioforme demonstrated decreased susceptibility to retapamulin. Based on inhibitory concentrations, retapamulin was more active than clindamycin, metronidazole and ceftriaxone against Propionibacterium acnes and anaerobic Gram-positive cocci, as all isolates were inhibited by <or=2 mg/L. CONCLUSIONS: At <or=2 mg/L, retapamulin inhibited 90% of all 232 anaerobes tested, whereas overall resistance rates for the comparators were as follows: co-amoxiclav, 2%; metronidazole, 12%; clindamycin, 15% and ceftriaxone, 20%. The broad anaerobic spectrum demonstrated by retapamulin in vitro is attractive. Pending further clinical investigation, retapamulin may offer an alternative treatment for anaerobic skin infections in this era of increasing resistance. SN - 0305-7453 UR - https://www.unboundmedicine.com/medline/citation/17350985/In_vitro_activity_against_anaerobes_of_retapamulin_a_new_topical_antibiotic_for_treatment_of_skin_infections_ L2 - https://academic.oup.com/jac/article-lookup/doi/10.1093/jac/dkm019 DB - PRIME DP - Unbound Medicine ER -